Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALILEO TAVR antithrombotic strategy trial
DRKS00010225Phase 3Terminated
- Sponsor
- Bayer
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in None and Atrial fibrillation (AFib) (2 arms), sponsored by Bayer. Started Mar 2016; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on DRKS00010225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00010225.